Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

yttrium Y 90-edotreotide

A radioconjugate consisting of the octreotide derivative edotreotide labeled with yttrium 90 (Y-90) with potential radiotherapeutic uses. Similar to octreotide, yttrium Y 90-edotreotide binds to somatostatin receptors (SSTRs), especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells, delivering tissue-specific, beta-emitting nuclide Y-90-mediated cytotoxicity to SSTR-positive cells. Yttrium Y 90-edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide and chelating the substituted octreotide to Y-90 via dodecanetetraacetic acid (DOTA).
Synonym:90Y-DOTA-3-Tyr-octreotide
Y90-DOTA-tyr3-octreotide
yttrium Y 90 -DOTATOC
yttrium Y 90 SMT 487
yttrium Y 90-DOTA-3-tyrosine-octreotide
US brand name:OctreoTher
Onalta
Y-90 OctreoTher
Search NCI's Drug Dictionary